首页> 美国卫生研究院文献>Haematologica >Rabbit antithymocyte globulin (Thymoglobulin®) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients
【2h】

Rabbit antithymocyte globulin (Thymoglobulin®) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients

机译:成年患者异基因造血干细胞移植后兔抗胸腺细胞球蛋白(Thymoglobulin®)损害常规和调节性CD4 + T细胞的胸腺输出

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rabbit antithymocyte globulin-Genzyme™ is used to prevent graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Common disadvantages of treatment are infectious complications. The effects of rabbit antithymocyte globulin-Genzyme™ on thymic function have not been well-studied. Multicolor flow cytometry was used to analyze the kinetics of conventional and regulatory T cells in adult patients treated (n=12) or not treated (n=8) with rabbit antithymocyte globulin-Genzyme™ during the first 6 months after allogeneic hematopoietic stem cell transplantation. Patients treated with rabbit antithymocyte globulin-Genzyme™ had almost undetectable levels of recent thymic emigrants (CD45RA+CD31+) of both conventional and regulatory CD4T cells throughout the 6 months after allogeneic hematopoietic stem cell transplantation whereas CD4+CD45RA-memory T cells were less affected, but their levels were also significantly lower than in patients not treated with rabbit antithymocyte globulin-Genzyme™. In vitro, rabbit antithymocyte globulin-Genzyme™ induced apoptosis and cytolysis of human thymocytes, and its cytotoxic effects were greater than those of rabbit antithymocyte globulin-Fresenius™. Rabbit antithymocyte globulin-Genzyme™ in combination with a conditioning regimen strongly impairs thymic recovery of both conventional and regulatory CD4+ T cells. The sustained depletion of conventional and regulatory CD4+T cells carries a high risk of both infections and graft-versus-host disease. Our data indicate that patients treated with rabbit antithymocyte globulin-Genzyme™ could benefit from thymus-protective therapies and that trials comparing this product with other rabbit antithymocyte globulin preparations or lymphocyte-depleting compounds would be informative.
机译:兔抗胸腺细胞球蛋白-Genzyme™用于预防异基因造血干细胞移植后的移植物抗宿主病。治疗的共同缺点是感染性并发症。尚未充分研究兔抗胸腺细胞球蛋白-Genzyme™对胸腺功能的影响。多色流式细胞术用于分析同种异体造血干细胞移植后头6个月内用兔抗胸腺细胞球蛋白Genzyme™治疗(n = 12)或未治疗(n = 8)的成年患者常规和调节性T细胞的动力学。在异基因治疗后的6个月中,用常规抗调节性CD4T细胞和常规调节性CD4T细胞治疗的兔抗胸腺细胞球蛋白Genzyme™患者的胸腺移出物(CD45RA + CD31 + )的水平几乎未检测到造血干细胞移植,而CD4 + CD45RA记忆T细胞受到的影响较小,但其水平也显着低于未用兔抗胸腺细胞球蛋白Genzyme™治疗的患者。在体外,兔抗胸腺细胞球蛋白-Genzyme™诱导人胸腺细胞凋亡和细胞溶解,其细胞毒性作用大于兔抗胸腺细胞球蛋白-Fresenius™。兔抗胸腺细胞球蛋白-Genzyme™与条件疗法相结合会强烈损害常规CD4 + T细胞的胸腺恢复。常规和调节性CD4 + T细胞的持续耗竭具有感染和移植物抗宿主病的高风险。我们的数据表明,用兔抗胸腺细胞球蛋白-Genzyme™治疗的患者可以受益于胸腺保护疗法,并且将该产品与其他兔抗胸腺细胞球蛋白制剂或消耗淋巴细胞的化合物进行比较的试验将是有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号